SANTEN PHARMACEUTICAL CO.,LTD. Logo

SANTEN PHARMACEUTICAL CO.,LTD.

A global company specializing in pharmaceuticals and medical devices for ophthalmology.

4536 | T

Overview

Corporate Details

ISIN(s):
JP3336000009
LEI:
Country:
Japan
Address:
大阪市北区大深町4番20号

Description

Santen Pharmaceutical Co., Ltd. is a global company specializing in ophthalmology. It is engaged in the research, development, manufacturing, sales, and marketing of pharmaceutical products and medical devices dedicated to eye health. The company's portfolio includes prescription and over-the-counter pharmaceuticals that address a wide range of ophthalmic conditions. Serving patients, consumers, and medical professionals in over 60 countries, Santen aims to contribute to the realization of “Happiness with Vision” by providing valuable products and services worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-13 03:29
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.8 KB
2025-02-14 02:01
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.3 KB
2025-01-15 06:49
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.0 KB
2024-12-13 03:01
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 28.5 KB
2024-11-14 05:33
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.7 KB
2024-11-11 07:32
確認書
Japanese 8.6 KB
2024-11-11 07:30
半期報告書-第113期(2024/04/01-2025/03/31)
Japanese 311.2 KB
2024-10-15 06:38
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.9 KB
2024-10-08 09:48
臨時報告書
Japanese 19.4 KB
2024-09-13 04:51
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.3 KB
2024-08-14 03:00
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.6 KB
2024-06-26 02:45
臨時報告書
Japanese 25.7 KB
2024-06-25 08:57
臨時報告書
Japanese 29.6 KB
2024-06-25 08:47
内部統制報告書-第112期(2023/04/01-2024/03/31)
Japanese 23.5 KB
2024-06-25 08:46
確認書
Japanese 8.5 KB

Automate Your Workflow. Get a real-time feed of all SANTEN PHARMACEUTICAL CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SANTEN PHARMACEUTICAL CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SANTEN PHARMACEUTICAL CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.